T-cell immunotherapy

A virus vector comprising:

• a constitutive promoter selected from the group consisting of human elongation factor 1 alpha (EF1a) promoter, cytomegalovirus (CMV) promoter and CAG promoter;
• a nucleic acid sequence encoding a chimeric antigen receptor (CAR), wherein
• the nucleic acid sequence encoding the CAR is under transcriptional control of the constitutive promoter;
• and
• the CAR comprises an extra-cellular antibody-derived single chain variable fragment (scFv) that binds specifically to an antigen, a transmembrane domain, and an intracellular signaling domain configured to transmit an activation signal upon binding of the antigen to the scFv;
• an inducible promoter comprising N nuclear factor of activated T-cells (NFAT) binding motifs followed by the minimal human interleukin 2 (IL-2) promoter;
• wherein
• N is 1-10;
• and
• the inducible promoter is activated by the activation signal;
• and
• a nucleic acid sequence encoding a Helicobacter pylori neutrophil activating protein (HP-NAP) and/or a nucleic acid sequence encoding an immunological equivalent fragment of the HP-NAP, wherein the nucleic acid sequence encoding the HP-NAP and/or the nucleic acid sequence encoding the immunological equivalent fragment of the HP-NAP is under transcriptional control of the inducible promoter.